(Q38545948)

4 September 2017

1 reference

title

A Major Review: Current Aspects of Ocular Behçet's Disease in Japan (English)

1 reference

4 September 2017

0 references

1 reference

Kenichi Namba

1

1 reference

4 September 2017

Hiroshi Goto

2

1 reference

4 September 2017

Toshikatsu Kaburaki

3

1 reference

4 September 2017

Nobuyoshi Kitaichi

4

1 reference

4 September 2017

Nobuhisa Mizuki

5

1 reference

4 September 2017

Yuri Asukata

6

1 reference

4 September 2017

Yujiro Fujino

7

1 reference

4 September 2017

Akira Meguro

8

1 reference

4 September 2017

Shunya Sakamoto

9

1 reference

4 September 2017

Etsuko Shibuya

10

1 reference

4 September 2017

Katsutoshi Yokoi

11

1 reference

4 September 2017

Shigeaki Ohno

12

1 reference

4 September 2017

1 January 2015

1 reference

Ocular Immunology and Inflammation

4 September 2017

1 reference

4 September 2017

23 Suppl 1

1 reference

4 September 2017

S1-23

1 reference

Epidemiological survey of intraocular inflammation in Japan

4 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

A study of comparison between the nationwide epidemiological survey in 1991 and previous surveys on behçet's disease in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Differential diagnosis of behçet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Clinical statistics of endogenous uveitis: comparison between general eye clinic and university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

The pathergy test and Behçet's syndrome in Britain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Skin prick test with self-saliva in patients with oral aphthoses: a diagnostic pathergy for Behcet's disease and recurrent aphthosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

The clinical significance of a pathergy reaction in patients with Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Guidelines for the diagnosis of ocular sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Intermediate uveitis in Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Effectiveness of cyclosporin therapy for Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Cyclosporin-A therapy in severe uveitis of Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Long-term therapy with low dose cyclosporin A in ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Cyclosporine: immunology, pharmacology and therapeutic uses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Effect of infliximab on gene expression profiling in Behcet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Effect of infliximab in progressive neuro-Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Use of infliximab and other biologics in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Azathioprine in severe uveitis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Low-dose interferon alfa-2a therapy in severe uveitis associated with Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2014.981547

10.3109/09273948.2014.981547

21 January 2018

Identifiers

DOI

1 reference

release_yjf25cdoazeadhztvgdeckl3se

4 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yjf25cdoazeadhztvgdeckl3se

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference